RFM
GSK icon

Royal Fund Management’s GSK GSK Stock Holding History

Royal Fund Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.89M Buy
36,119
+578
+2% +$30.6K 0.16% 152
2026
Q1 		$1.96M Buy
35,541
+748
+2% +$40.5K 0.19% 138
2025
Q4 		$1.71M Buy
34,793
+8,024
+30% +$374K 0.16% 141
2025
Q3 		$1.16M Sell
26,769
-2,503
-9% -$97.8K 0.14% 150
2025
Q2 		$1.12M Buy
29,272
+3,502
+14% +$134K 0.11% 184
2025
Q1 		$999K Buy
25,770
+1,745
+7% +$63.9K 0.11% 195
2024
Q4 		$813K Sell
24,025
-18,431
-43% -$663K 0.08% 190
2024
Q3 		$1.74M Buy
42,456
+19,758
+87% +$808K 0.1% 173
2024
Q2 		$875K Sell
22,698
-2,133
-9% -$89.7K 0.07% 199
2024
Q1 		$1.06M Buy
24,831
+442
+2% +$18.2K 0.1% 196
2023
Q4 		$904K Buy
24,389
+1,065
+5% +$38.2K 0.1% 191
2023
Q3 		$846K Buy
23,324
+1,104
+5% +$39.2K 0.11% 180
2023
Q2 		$792K Sell
22,220
-1,589
-7% -$57K 0.1% 182
2023
Q1 		$847K Buy
23,809
+3,338
+16% +$117K 0.12% 168
2022
Q4 		$719K Buy
20,471
+2,201
+12% +$73.3K 0.11% 151
2022
Q3 		$537K Buy
18,270
+6,171
+51% +$234K 0.1% 145
2022
Q2 		$658K Buy
12,099
+4,949
+69% +$273K 0.11% 131
2022
Q1 		$389K Buy
7,150
+1,237
+21% +$67.2K 0.06% 162
2021
Q4 		$325K Buy
5,913
+799
+16% +$41.6K 0.05% 156
2021
Q3 		$244K Buy
5,114
+558
+12% +$28K 0.04% 168
2021
Q2 		$226K Buy
+4,556
New +$219K 0.04% 177
2020
Q4 		– Sell
-4,306
Closed -$202K – 182
2020
Q3 		$202K Sell
4,306
-56
-1% -$2.81K 0.05% 161
2020
Q2 		$222K Sell
4,362
-1,981
-31% -$102K 0.08% 135
2020
Q1 		$300K Buy
6,343
+685
+12% +$36.5K 0.12% 104
2019
Q4 		$332K Buy
5,658
+809
+17% +$45K 0.08% 110
2019
Q3 		$258K Buy
4,849
+74
+2% +$3.81K 0.07% 114
2019
Q2 		$238K Sell
4,775
-191
-4% -$9.58K 0.07% 116
2019
Q1 		$259K Buy
4,966
+572
+13% +$28.6K 0.08% 110
2018
Q4 		$209K Buy
4,394
+147
+3% +$7.24K 0.08% 105
2018
Q3 		$213K Buy
4,247
+900
+27% +$45.7K 0.07% 113
2018
Q2 		$168K Sell
3,347
-1,667
-33% -$84K 0.06% 121
2018
Q1 		$244K Sell
5,014
-50
-1% -$2.33K 0.09% 106
2017
Q4 		$224K Sell
5,064
-76,728
-94% -$3.54M 0.08% 106
2017
Q3 		$4.15M Sell
81,792
-17,547
-18% -$890K 1.65% 24
2017
Q2 		$5.35M Sell
99,339
-6,051
-6% -$323K 2.27% 19
2017
Q1 		$5.55M Buy
105,390
+8,097
+8% +$411K 2.68% 18
2016
Q4 		$4.68M Buy
+97,293
New +$4.81M 2.6% 16

Other funds holding GSK

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
DLA
Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
SIS
Sound Income Strategies Ft Lauderdale, Florida $2.23B AUM 11.22% 1-Year Est. Return
KFP
Keystone Financial Planning Cleveland, Ohio $388M AUM 16.66% 1-Year Est. Return
QCM
QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return
TH
Transmarket Holdings Chicago, Illinois $136M AUM
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return
BB
Bell Bank Fargo, North Dakota $2.62B AUM 23.93% 1-Year Est. Return

Royal Fund Management's GSK Position: Q2 2026 in Review

Royal Fund Management increased its GSK (GSK) stake by 1.6% in Q2 2026, buying an estimated $30.6K and bringing the position to 36,119 shares worth $1.89M. The position accounts for 0.16% of the portfolio, ranked #152.

Royal Fund Management first reported a position in GSK in Q4 2016 and has held it in 37 quarters since. The position peaked at $5.55M in Q1 2017. 215 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Royal Fund Management held 36,119 shares of GSK worth $1.89M as of Q2 2026.
  • Royal Fund Management bought 578 GSK shares in Q2 2026, an estimated $30.6K.
  • GSK made up 0.16% of Royal Fund Management's portfolio in Q2 2026, its #152 holding.
  • Royal Fund Management first reported a position in GSK in Q4 2016 and has held it in 37 quarters since.
  • Royal Fund Management's GSK position peaked at $5.55M in Q1 2017.
  • 215 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Royal Fund Management's 13F filing for Q2 2026, filed 20 Jul 2026.